Meeting
2024 ASCO Breakthrough
Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.
Authors
Masatoshi Kudo
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan
Masatoshi Kudo , Stephen Lam Chan , Bruno Sangro , Joseph P. Erinjeri , Shukui Qin , Zhenggang Ren , Yasuaki Arai , Valeriy Vladimirovich Breder , Shi-Ming Lin , Jean-Marie Peron , Tien Quang Nguyen , Lunan Yan , Chang-Fang Chiu , Florinda A. Santos , Anil Veluvolu , Satheesh Chiradoni Thungappa , Claire Morgan , Kerry Parsons , Ioannis Xynos , Riccardo Lencioni
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Gastrointestinal Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Quality of Care,Healthcare Equity and Access to Care,Population Health,Viral-Mediated Malignancies
Sub Track
Immunotherapies
Clinical Trial Registration Number
NCT03778957
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 65)
DOI
10.1200/JCO.2024.42.23_suppl.65
Abstract #
65
Poster Bd #
D7
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.
First Author: Stephen Lam Chan
Poster
2023 ASCO Annual Meeting
Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.
First Author: Kazuomi Ueshima
Poster
2023 ASCO Annual Meeting
Phase I/II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma: Final results.
First Author: Houda Bahig
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.
First Author: Thomas J. George